Summary: Beta-amyloid peptide (beta-APP)
Pfam includes annotations and additional family information from a range of different sources. These sources can be accessed via the tabs below.
This is the Wikipedia entry entitled "Beta amyloid". More...
The Wikipedia text that you see displayed here is a download from Wikipedia. This means that the information we display is a copy of the information from the Wikipedia database. The button next to the article title ("Edit Wikipedia article") takes you to the edit page for the article directly within Wikipedia. You should be aware you are not editing our local copy of this information. Any changes that you make to the Wikipedia article will not be displayed here until we next download the article from Wikipedia. We currently download new content on a nightly basis.
Does Pfam agree with the content of the Wikipedia entry ?
Pfam has chosen to link families to Wikipedia articles. In some case we have created or edited these articles but in many other cases we have not made any direct contribution to the content of the article. The Wikipedia community does monitor edits to try to ensure that (a) the quality of article annotation increases, and (b) vandalism is very quickly dealt with. However, we would like to emphasise that Pfam does not curate the Wikipedia entries and we cannot guarantee the accuracy of the information on the Wikipedia page.
Editing Wikipedia articles
Before you edit for the first time
Wikipedia is a free, online encyclopedia. Although anyone can edit or contribute to an article, Wikipedia has some strong editing guidelines and policies, which promote the Wikipedia standard of style and etiquette. Your edits and contributions are more likely to be accepted (and remain) if they are in accordance with this policy.
You should take a few minutes to view the following pages:
How your contribution will be recorded
Anyone can edit a Wikipedia entry. You can do this either as a new user or you can register with Wikipedia and log on. When you click on the "Edit Wikipedia article" button, your browser will direct you to the edit page for this entry in Wikipedia. If you are a registered user and currently logged in, your changes will be recorded under your Wikipedia user name. However, if you are not a registered user or are not logged on, your changes will be logged under your computer's IP address. This has two main implications. Firstly, as a registered Wikipedia user your edits are more likely seen as valuable contribution (although all edits are open to community scrutiny regardless). Secondly, if you edit under an IP address you may be sharing this IP address with other users. If your IP address has previously been blocked (due to being flagged as a source of 'vandalism') your edits will also be blocked. You can find more information on this and creating a user account at Wikipedia.
If you have problems editing a particular page, contact us at firstname.lastname@example.org and we will try to help.
The community annotation is a new facility of the Pfam web site. If you have problems editing or experience problems with these pages please contact us.
Beta amyloid Edit Wikipedia article
||This article may be too technical for most readers to understand. (January 2011)|
|Beta-amyloid peptide (beta-APP)|
A partially folded structure of amyloid-beta(1 40) in an aqueous environment (pdb 2lfm)
|amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease)|
Processing of the amyloid precursor protein
|Locus||Chr. 21 q21.2|
Amyloid beta (AÎ² or Abeta) is a peptide of 36â43 amino acids that is processed from the amyloid precursor protein (APP). While best known as a component of amyloid plaques in association with Alzheimer's disease, as AÎ² is the main component of certain deposits found in the brains of patients with Alzheimer's disease, evidence has been found that AÎ² is a highly multifunctional peptide with significant non-pathological activity. A recent study suggested that APP and its amyloid potential is of ancient origins, dating as far back as early deuterostomes.
The normal function of AÎ² is not well understood. Though some animal studies have shown that the absence of AÎ² does not lead to any loss of physiological function, several potential activities have been discovered for AÎ², including activation of kinase enzymes, protection against oxidative stress, regulation of cholesterol transport, functioning as a transcription factor, and anti-microbial activity (potentially associated with AÎ²'s pro-inflammatory activity).
AÎ² is the main component of amyloid plaques (deposits found in the brains of patients with Alzheimer's disease). Similar plaques appear in some variants of Lewy body dementia and in inclusion body myositis (a muscle disease), while AÎ² can also form the aggregates that coat cerebral blood vessels in cerebral amyloid angiopathy. The plaques are composed of a tangle of regularly ordered fibrillar aggregates called amyloid fibers, a protein fold shared by other peptides such as the prions associated with protein misfolding diseases. Recent research suggests that soluble oligomeric forms of the peptide may be causative agents in the development of Alzheimer's disease. A number of genetic, cell biology, biochemical and animal studies support the concept that AÎ² plays a central role in the development of Alzheimerâs disease pathology.
Brain AÎ² is elevated in patients with sporadic Alzheimerâs disease. AÎ² is the main constituent of brain parenchymal and vascular amyloid; it contributes to cerebrovascular lesions and is neurotoxic. It is unresolved how AÎ² accumulates in the central nervous system and subsequently initiates the disease of cells. Some researchers have found that the AÎ² oligomers induce some of the symptoms of Alzheimer's Disease by competing with insulin for binding sites on the insulin receptor, thus impairing glucose metabolism in the brain. Significant efforts have been focused on the mechanisms responsible for AÎ² production, including the proteolytic enzymes alpha- and Î²-secretases which generate AÎ² from its precursor protein, APP (amyloid precursor protein). AÎ² circulates in plasma, cerebrospinal fluid (CSF) and brain interstitial fluid (ISF) mainly as soluble AÎ²40 Senile plaques contain both AÎ²40 and AÎ²42, while vascular amyloid is predominantly the shorter AÎ²40. Several sequences of AÎ² were found in both lesions. Generation of AÎ² in the CNS may take place in the neuronal axonal membranes after APP-mediated axonal transport of Î²-secretase and presenilin-1.
AÎ² is formed after sequential cleavage of the amyloid precursor protein (APP), a transmembrane glycoprotein of undetermined function. APP can be cleaved by the proteolytic enzymes Î±-, Î²- and Î³-secretase; AÎ² protein is generated by successive action of the Î² and Î³ secretases. The Î³ secretase, which produces the C-terminal end of the AÎ² peptide, cleaves within the transmembrane region of APP and can generate a number of isoforms of 36-43 amino acid residues in length. The most common isoforms are AÎ²40 and AÎ²42; the longer form is typically produced by cleavage that occurs in the endoplasmic reticulum, while the shorter form is produced by cleavage in the trans-Golgi network. The AÎ²40 form is the more common of the two, but AÎ²42 is the more fibrillogenic and is thus associated with disease states. Mutations in APP associated with early-onset Alzheimer's have been noted to increase the relative production of AÎ²42, and thus one suggested avenue of Alzheimer's therapy involves modulating the activity of Î² and Î³ secretases to produce mainly AÎ²40. AÎ² is destroyed by several amyloid-degrading enzymes including neprilysin.
Autosomal-dominant mutations in APP cause hereditary early-onset Alzheimer's disease (familial AD). This form of AD accounts for no more than 10% of all cases, and the vast majority of AD is not accompanied by such mutations. However, familial Alzheimer disease is likely to result from altered proteolytic processing. Increases in either total AÎ² levels or the relative concentration of both AÎ²40 and AÎ²42 (where the former is more concentrated in cerebrovascular plaques and the latter in neuritic plaques) have been implicated in the pathogenesis of both familial and sporadic Alzheimer's disease. Due to its more hydrophobic nature, the AÎ²42 is the most amyloidogenic form of the peptide. However the central sequence KLVFFAE is known to form amyloid on its own, and probably forms the core of the fibril.
The "amyloid hypothesis", that the plaques are responsible for the pathology of Alzheimer's disease, is accepted by the majority of researchers but is by no means conclusively established. An alternative hypothesis is that amyloid oligomers rather than plaques are responsible for the disease. Mice that are genetically engineered to express oligomers but not plaques (APPE693Q) develop the disease. Furthermore mice that are in addition engineered to convert oligomers into plaques (APPE693Q X PS1ÎE9), are no more impaired than the oligomer only mice. Intra-cellular deposits of tau protein are also seen in the disease, and may also be implicated, as has aggregation of alpha synuclein.
Structure and Toxicity
Amyloid beta is commonly thought to be intrinsically unstructured, meaning that in solution it does not acquire a unique tertiary fold but rather populates a set of structures. As such, it cannot be crystallized and most structural knowledge on amyloid beta comes from NMR and molecular dynamics. Early NMR-derived models of a 26-aminoacid polypeptide from amyloid beta (AÎ² 10-35) show a collapsed coil structure devoid of significant secondary structure content, however, the most recent (2012) NMR structure of (AÎ² 1-40) has significant secondary and tertiary structure. Replica exchange molecular dynamics studies suggested that amyloid beta can indeed populate multiple discrete structural states; more recent studies identified a multiplicity of discrete conformational clusters by statistical analysis. By NMR-guided simulations, amyloid beta 1-40 and amyloid beta 1-42 also seem to feature highly different conformational states, with the C-terminus of amyloid beta 1-42 being more structured than that of the 1-40 fragment.
Structural information on the oligomeric state of amyloid beta is still sparse as of 2010. Low-temperature and low-salt conditions allowed to isolate pentameric disc-shaped oligomers devoid of beta structure. In contrast, soluble oligomers prepared in the presence of detergents seem to feature substantial beta sheet content with mixed parallel and antiparallel character, different from fibrils; computational studies suggest an antiparallel beta-turn-beta motif instead for membrane-embedded oligomers.
The mechanism by which amyloid beta may damage and kill neurons is by generating reactive oxygen species during the process of its self-aggregation. When this occurs on the membrane of neurons it causes lipid peroxidation and the generation of a toxic aldehyde called 4-hydroxynonenal which, in turn, impairs the function of ion-motive ATPases, glucose transporters and glutamate transporters. As a result of amyloid beta promotes depolarization of the synaptic membrane, excessive calcium influx and mitochondrial impairment.
Researchers in Alzheimer's disease have identified five strategies as possible interventions against amyloid:
- Î²-Secretase inhibitors. These work to block the first cleavage of APP outside of the cell.
- Î³-Secretase inhibitors (e. g. semagacestat). These work to block the second cleavage of APP in the cell membrane and would then stop the subsequent formation of AÎ² and its toxic fragments.
- Selective AÎ²42 lowering agents (e. g. tarenflurbil). These modulate Î³-secretase to reduce AÎ²42 production in favor of other (shorter) AÎ² versions.
Î²- and y-secretase are responsible for the generation of AÎ² from the release of the intracellular domain of APP, meaning that compounds that can partially inhibit the activity of either Î²- and y-secretase are highly sought after. In order to initiate partial inhibition of Î²- and y-secretase, a compound is needed that can block the large active site of aspartyl proteases while still being capable of bypassing the blood-brain barrier. To date, human testing has been avoided due to concern that it might interfere with signaling via Notch proteins and other cell surface receptors.
- Immunotherapy. This stimulates the host immune system to recognize and attack AÎ², or provide antibodies that either prevent plaque deposition or enhance clearance of plaques or AÎ² oligomers. Oligomerization is a chemical process that converts individual molecules into a chain consisting of a finite number of molecules. Prevention of oligomerization of AÎ² has been exemplified by active or passive AÎ² immunization. In this process antibodies to AÎ² are used to decrease cerebral plaque levels. This is accomplished by promoting microglial clearance and/or redistributing the peptide from the brain to systemic circulation. One such beta-amyloid vaccine that is currently in clinical trials is CAD106. Immunization with synthetic AÎ²1-42 has been shown to be beneficial in mice and displays low toxicity; however human trials have shown no significant differences. Thus, it is not yet effective in humans and requires further research. Specific findings show that the 20 amino acid SDPM1 protein binds tetramer forms of AÎ²(1-40)- and AÎ²(1-42)-amyloids and blocks subsequent AÎ² amyloid aggregation. It is important to note that this study was done in mice and that while it prevents further development of neuropathology it did not result in an improvement in cognitive performance. Lastly, AÎ²42 immunization resulted in the clearance of amyloid plaques in patients with Alzheimer's disease but did not prevent progressive neurodegeneration.
- Anti-aggregation agents such as apomorphine. These prevent AÎ² fragments from aggregating or clear aggregates once they are formed. Studies comparing synthetic to recombinant AÎ²42 in assays measuring rate of fibrillation, fibril homogeneity, and cellular toxicity showed that recombinant AÎ²42 had a faster fibrillation rate and greater toxicity than synthetic Amyloid beta 1-42 peptide. This observation combined with the irreproducibility of certain AÎ²42 experimental studies has been suggested to be responsible for the lack of progress in Alzheimerâs research. Consequently, there has been renewed efforts to manufacture AÎ²42 and other amyloid peptides at unprecedented (>99%) purity
There is some indication that supplementation of the hormone melatonin may be effective against amyloid. Melatonin interacts with amyloid beta and inhibits its aggregation This anti-aggregatory activity occurs only through an interaction with dimers of the soluble amyloid beta peptide. Melatonin does not reverse fibril formation or oligomers of amyloid beta once they are formed. This is supported by experiments in transgenic mice which suggest that melatonin has the potential to prevent amyloid deposition if administered early in life, but it may not be efficacious to revert amyloid deposition or treat Alzheimer's disease.
This connection with melatonin, which regulates sleep, is strengthened by the recent research showing that the wakefulness inducing hormone orexin influences amyloid beta (see below). Interestingly, animal experiments show that melatonin may also correct mild elevations of cholesterol which is also an early risk factor for amyloid formation.
The cannabinoid HU-210 has been shown to prevent amyloid beta-promoted inflammation. The endocannabinoids anandamide and noladin ether have also been shown to be neuroprotective against amyloid beta in vitro.
It has been shown that high-cholesterol diets tend to increase AÎ² pathology in animals. Modulating cholesterol homeostasis has yielded results that show that chronic use of cholesterol-lowering drugs, such as the statins, is associated with a lower incidence of AD. In APP genetically modified mice, cholesterol-lowering drugs have been shown to reduce overall pathology. While the mechanism is poorly understood it appears that cholesterol-lowering drugs have a direct effect on APP processing.
Chelation therapy, which involves the removal of heavy metals from the body, has also been shown to be beneficial in lowering amyloid plaque levels. This is because AÎ² aggregation is somewhat dependent on the metal ions copper and zinc. Zinc in synaptic vesicles, which is under the control of the zinc transporter ZnT3, plays a major role in AÎ² formation. The expression of the ZnT3 is significantly lower in Alzheimerâs patients compared to healthy patients. Mice without ZnT3 were found to have much lower plaque formation. Further promoting this concept, AÎ² deposition was impeded in APP transgenic mice treated with the antibiotic clioquinol, a known copper/zinc chelator.
Drug therapy has been another approach to treatment. Memantine is an Alzheimerâs drug which has received widespread approval. It is a non-competitive N-methyl-D-aspartate (NMDA) channel blocker. By binding to the NMDA receptor with a higher affinity than Mg2+ ions, memantine is able to inhibit the prolonged influx of Ca2+ ions, particularly from extrasynaptic receptors, which forms the basis of neuronal excitotoxicity. It is an option for the management of patients with moderate to severe Alzheimer's Disease (modest effect). The study showed that 20 mg/day improved cognition, functional ability and behavioural symptoms in patient population.
Another drug that is currently under research is victoza, which is typically used as a diabetes drug. Treatment with victoza yielded cognitive benefits that included improved object and spatial recognition. Additionally victoza enhances induction and maintenance of long term potentiation (LTP) and paired-pulse facilitation (PPF) in both APP/PS1 and non-genetically altered mice. Other histological benefits include a reduced inflammatory response and an increase in the number of young neurons in the dentate gyrus. The Î²-amyloid level was also found to be significantly reduced.
Circadian rhythm of amyloid beta
A 2009 report demonstrated that amyloid beta production follows a circadian rhythm, rising when an animal (mouse) or person is awake and falling during sleep. The wakefulness-promoting neuroprotein orexin was shown to be necessary for the circadian rhythm of amyloid beta production. The report suggested that excessive periods of wakefulness (i.e. due to sleep debt) could cause chronic build-up of amyloid beta, which could hypothetically lead to Alzheimer's disease. This is consistent with recent findings that chronic sleep deprivation is associated with early onset Alzheimer's disease.
Melatonin is also involved in circadian rhythm maintenance. Notably, melatonin has been connected with the "sundowning" phenomenon, in which Alzheimer's disease patients that have amyloid plaques in the hypothalamus exhibit exacerbation of Alzheimer's disease symptoms late in the day. This "sundowning" phenomenon could be directly or indirectly related to the recently discovered continuous increase in amyloid beta throughout the day.
Measuring amyloid beta
There are many different ways to measure Amyloid beta. It can be measured semi-quantitatively with immunostaining, which also allows one to determine location. Amyloid beta may be primarily vascular, as in cerebral amyloid angiopathy, or in senile plaques and vascular.
Imaging compounds, notably Pittsburgh compound B, (6-OH-BTA-1, a thioflavin), can selectively bind to amyloid beta in vitro and in vivo. This technique, combined with PET imaging, has been used to image areas of plaque deposits in Alzheimer's patients.
Dual polarisation interferometry is an optical technique which can measure the very earliest stages of aggregration and inhibition by measuring the molecular size and densities as the fibrils elongate. These aggregate processes can also be studied on lipid bilayer constructs.
- Vivekanandan S, Brender JR, Lee SY, Ramamoorthy A (July 2011). "A partially folded structure of amyloid-beta(1-40) in an aqueous environment". Biochem. Biophys. Res. Commun. 411 (2): 312â6. doi:10.1016/j.bbrc.2011.06.133. PMC 3148408. PMID 21726530.
- Lahiri DK, Maloney B (September 2010). "Beyond the signaling effect role of amyloidâÎ²42 on the processing of AÎ²PP, and its clinical implications". Exp. Neurol. 225 (1): 51â4. doi:10.1016/j.expneurol.2010.04.018. PMC 2922469. PMID 20451519.
- Sarkar IN, Tharp G (April 2013). "Origins of amyloid-beta.". BMC Genomics 14 (1): 290. doi:10.1186/1471-2164-14-290. PMID 23627794.
- Hiltunen M, van Groen T, Jolkkonen J (2009). "Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies". J. Alzheimers Dis. 18 (2): 401â12. doi:10.3233/JAD-2009-1154. PMID 19584429.
- Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, Yan Q, Vassar R, Citron M (October 2003). "BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time". Neurobiol. Dis. 14 (1): 81â8. doi:10.1016/S0969-9961(03)00104-9. PMID 13678669.
- Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK (March 2004). "Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential". Biochim. Biophys. Acta 1697 (1â2): 89â101. doi:10.1016/j.bbapap.2003.11.016. PMID 15023353.
- Tabaton M, Zhu X, Perry G, Smith MA, Giliberto L (January 2010). "Signaling Effect of Amyloid-Î²42 on the Processing of AÎ²PP". Exp. Neurol. 221 (1): 18â25. doi:10.1016/j.expneurol.2009.09.002. PMC 2812589. PMID 19747481.
- Zou K, Gong JS, Yanagisawa K, Michikawa M (June 2002). "A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage". J. Neurosci. 22 (12): 4833â41. PMID 12077180.
- Baruch-Suchodolsky R, Fischer B (May 2009). "Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems". Biochemistry 48 (20): 4354â70. doi:10.1021/bi802361k. PMID 19320465.
- Yao ZX, Papadopoulos V (October 2002). "Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity". FASEB J. 16 (12): 1677â9. doi:10.1096/fj.02-0285fje. PMID 12206998.
- Igbavboa U, Sun GY, Weisman GA, He Y, Wood WG (August 2009). "Amyloid Î²-Protein Stimulates Trafficking of Cholesterol and Caveolin-1 from the Plasma Membrane to the Golgi Complex in Mouse Primary Astrocytes". Neuroscience 162 (2): 328â38. doi:10.1016/j.neuroscience.2009.04.049. PMC 3083247. PMID 19401218.
- Maloney B, Lahiri DK (June 2011). "The Alzheimer's amyloid Î²-peptide (AÎ²) binds a specific DNA AÎ²-interacting domain (AÎ²ID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif". Gene 488 (1â2): 1â12. doi:10.1016/j.gene.2011.06.004. PMC 3381326. PMID 21699964.
- Bailey JA, Maloney B, Ge YW, Lahiri DK (June 2011). "Functional activity of the novel Alzheimer's amyloid Î²-peptide interacting domain (AÎ²ID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis". Gene 488 (1â2): 13â22. doi:10.1016/j.gene.2011.06.017. PMC 3372404. PMID 21708232.
- Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010). "The Alzheimer's Disease-Associated Amyloid Î²-Protein Is an Antimicrobial Peptide". In Bush, Ashley I. PLoS ONE 5 (3): e9505. Bibcode:2010PLoSO...5.9505S. doi:10.1371/journal.pone.0009505. PMC 2831066. PMID 20209079.
- Parker MH, Reitz AB (2000). "Assembly of Î²-Amyloid Aggregates at the Molecular Level". Chemtracts-Organic Chemistry 13 (1): 51â56.
- Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (August 2008). "Amyloid Î²-Protein Dimers Isolated Directly from Alzheimer Brains Impair Synaptic Plasticity and Memory". Nat. Med. 14 (8): 837â42. doi:10.1038/nm1782. PMC 2772133. PMID 18568035. Lay summary â Fox News.
- Prelli F, CastaÃ±o E, Glenner GG, Frangione B (August 1988). "Differences between vascular and plaque core amyloid in Alzheimer's disease". J. Neurochem. 51 (2): 648â51. doi:10.1111/j.1471-4159.1988.tb01087.x. PMID 3292706.
- Ghiso J, Frangione B (December 2002). "Amyloidosis and Alzheimer's disease". Adv. Drug Deliv. Rev. 54 (12): 1539â51. doi:10.1016/S0169-409X(02)00149-7. PMID 12453671.
- Selkoe DJ (October 2001). "Clearing the brain's amyloid cobwebs". Neuron 32 (2): 177â80. doi:10.1016/S0896-6273(01)00475-5. PMID 11683988.
- Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M (September 1998). "Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau". Nat. Neurosci. 1 (5): 355â8. doi:10.1038/1565. PMID 10196523.
- Roses AD (February 1998). "Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases". Am. J. Med. Genet. 81 (1): 49â57. doi:10.1002/(SICI)1096-8628(19980207)81:1<49::AID-AJMG10>3.0.CO;2-W. PMID 9514588.
- Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (May 2002). "Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor". J. Neurosci. 22 (10): RC221. PMID 12006603.
- Ray WJ, Yao M, Mumm J, Schroeter EH, Saftig P, Wolfe M, Selkoe DJ, Kopan R, Goate AM (December 1999). "Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch". J. Biol. Chem. 274 (51): 36801â7. doi:10.1074/jbc.274.51.36801. PMID 10593990.
- Roberts SB (December 2002). "Î³-secretase inhibitors and Alzheimer's disease". Adv. Drug Deliv. Rev. 54 (12): 1579â88. doi:10.1016/S0169-409X(02)00155-2. PMID 12453675.
- Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (October 1999). "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE". Science 286 (5440): 735â41. doi:10.1126/science.286.5440.735. PMID 10531052.
- Vassar R (December 2002). "Beta-secretase (BACE) as a drug target for Alzheimer's disease". Adv. Drug Deliv. Rev. 54 (12): 1589â602. doi:10.1016/S0169-409X(02)00157-6. PMID 12453676.
- Zlokovic BV, Frangione B (2003). Transport-clearance hypothesis for Alzheimerâs disease and potential therapeutic implications. Landes Bioscience. pp. 114â122.
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (June 1985). "Amyloid plaque core protein in Alzheimer disease and Down syndrome". Proc. Natl. Acad. Sci. U.S.A. 82 (12): 4245â9. Bibcode:1985PNAS...82.4245M. doi:10.1073/pnas.82.12.4245. PMC 397973. PMID 3159021.
- CastaÃ±o EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B (December 1996). "The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease". J. Biol. Chem. 271 (50): 32185â91. doi:10.1074/jbc.271.50.32185. PMID 8943274.
- Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ (November 1993). "beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease". Proc. Natl. Acad. Sci. U.S.A. 90 (22): 10836â40. Bibcode:1993PNAS...9010836R. doi:10.1073/pnas.90.22.10836. PMC 47873. PMID 8248178.
- Shinkai Y, Yoshimura M, Ito Y, Odaka A, Suzuki N, Yanagisawa K, Ihara Y (September 1995). "Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels". Ann. Neurol. 38 (3): 421â8. doi:10.1002/ana.410380312. PMID 7668828.
- Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (December 2001). "Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP". Nature 414 (6864): 643â8. doi:10.1038/414643a. PMID 11740561.
- Hartmann T, Bieger SC, BrÃ¼hl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (September 1997). "Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides". Nat. Med. 3 (9): 1016â20. doi:10.1038/nm0997-1016. PMID 9288729.
- Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM (August 2007). "Î³-Secretase Substrate Concentration Modulates the AÎ²42/AÎ²40 Ratio: Implications for Alzheimer's disease". J. Biol. Chem. 282 (32): 23639â44. doi:10.1074/jbc.M704601200. PMID 17556361.
- Nalivaeva NN, Belyaev ND, Zhuravin IA, Turner AJ (2012). "The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?". Int J Alzheimers Dis 2012: 383796. doi:10.1155/2012/383796. PMC 3412116. PMID 22900228.
- Maslow K (March 2008). "2008 Alzheimer's disease facts and figures". Alzheimers Dement 4 (2): 110â33. doi:10.1016/j.jalz.2008.02.005. PMID 18631956.
- Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (September 1999). "Soluble Amyloid Î² Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease". Am. J. Pathol. 155 (3): 853â62. doi:10.1016/S0002-9440(10)65184-X. PMC 1866907. PMID 10487842.
- Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (April 2003). "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis". Science 300 (5618): 486â9. Bibcode:2003Sci...300..486K. doi:10.1126/science.1079469. PMID 12702875.
- Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy EF, Checler F, Glabe C, Bilker W, Abel T, Schmeidler J, Ehrlich ME (2010). "Days-to-criterion as an indicator of toxicity associated with human Alzheimer amyloid-Î² oligomers". Annals of Neurology 67 (6): 220â30. doi:10.1002/ana.22052. PMC 3094694. PMID 20641005. Lay summary â Drug Discovery and Development.
- Zhang S, Iwata K, Lachenmann MJ, Peng JW, Li S, Stimson ER, Lu Y, Felix AM, Maggio JE, Lee JP (June 2000). "The Alzheimer's peptide a beta adopts a collapsed coil structure in water". J. Struct. Biol. 130 (2-3): 130â41. doi:10.1006/jsbi.2000.4288. PMID 10940221.
- Yang M, Teplow DB (December 2008). "Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences". J. Mol. Biol. 384 (2): 450â64. doi:10.1016/j.jmb.2008.09.039. PMC 2673916. PMID 18835397.
- Sgourakis NG, Merced-Serrano M, Boutsidis C, Drineas P, Du Z, Wang C, Garcia AE (January 2011). "Atomic-level characterization of the ensemble of the AÎ²(1-42) monomer in water using unbiased molecular dynamics simulations and spectral algorithms". J. Mol. Biol. 405 (2): 570â83. doi:10.1016/j.jmb.2010.10.015. PMC 3060569. PMID 21056574.
- Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE (May 2007). "The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD / NMR study". J. Mol. Biol. 368 (5): 1448â57. doi:10.1016/j.jmb.2007.02.093. PMC 1978067. PMID 17397862.
- Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO (May 2010). "Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils". Nat. Struct. Mol. Biol. 17 (5): 561â7. doi:10.1038/nsmb.1799. PMC 2922021. PMID 20383142.
- Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, Miesbauer L, Solomon L, Bartley D, Walter K, Johnson RW, Hajduk PJ, Olejniczak ET (March 2009). "Structural characterization of a soluble amyloid beta-peptide oligomer". Biochemistry 48 (9): 1870â7. doi:10.1021/bi802046n. PMID 19216516.
- Strodel B, Lee JW, Whittleston CS, Wales DJ (September 2010). "Transmembrane structures for Alzheimer's AÎ²(1-42) oligomers". J. Am. Chem. Soc. 132 (38): 13300â12. doi:10.1021/ja103725c. PMID 20822103.
- Mattson MP (August 2004). "Pathways towards and away from Alzheimer's disease". Nature 430 (7000): 631â9. doi:10.1038/nature02621. PMC 3091392. PMID 15295589.
- Citron M (September 2004). "Strategies for disease modification in Alzheimer's disease". Nat. Rev. Neurosci. 5 (9): 677â85. doi:10.1038/nrn1495. PMID 15322526.
- Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (June 2012). "Safety, tolerability, and antibody response of active AÎ² immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study". Lancet Neurol 11 (7): 597â604. doi:10.1016/S1474-4422(12)70140-0. PMID 22677258. Lay summary â Karolinska Institutet.
- Wang CM, Devries S, Camboni M, Glass M, Martin PT (September 2010). "Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease". Neurobiol. Dis. 39 (3): 409â22. doi:10.1016/j.nbd.2010.05.013. PMC 2913404. PMID 20493257.
- Lashuel, H. A.; Hartley, D. M.; Balakhaneh, D.; Aggarwal A.; Teichberg S.; Callaway, D. J. E. (November 2002). "New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease". J. Biol. Chem. 277 (45): 42881â90. doi:10.1074/jbc.M206593200. PMID 12167652.
- Parker MH, Chen R, Conway KA, Lee DH, Luo C, Boyd RE, Nortey SO, Ross TM, Scott MK, Reitz AB (November 2002). "Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation". Bioorg. Med. Chem. 10 (11): 3565â9. doi:10.1016/S0968-0896(02)00251-1. PMID 12213471.
- finder, v; glockshuber (2009). "The Recombinant Amyloid-Î² Peptide AÎ²1â42 Aggregates Faster and Is More Neurotoxic than Synthetic AÎ²1â42". journal of molecular biology 396: 9â18. doi:10.1016/j.jmb.2009.12.016.
- Editor. "State of Aggregation". Nature Neuroscience 14: 399. doi:10.1038/nn0411-399.
- "BioPure Amyloid Peptides".
- Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J (March 1998). "Inhibition of Alzheimer's beta fibrillogenesis by melatonin". J Biol Chem 273 (13): 7185â7188. doi:10.1074/jbc.273.13.7185. PMID 9516407.
- Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH (November 2005). "Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases". Ann. N. Y. Acad. Sci. 1056: 430â49. Bibcode:2005NYASA1056..430L. doi:10.1196/annals.1352.008. PMID 16387707.
- Wang XC, Zhang YC, Chatterjie N, Grundke-Iqbal I, Iqbal K, Wang JZ (June 2008). "Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells". Neurochem. Res. 33 (6): 1138â44. doi:10.1007/s11064-007-9563-y. PMID 18231852.
- Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM (November 2009). "Amyloid-Î² Dynamics are Regulated by Orexin and the Sleep-Wake Cycle". Science 326 (5955): 1005â7. Bibcode:2009Sci...326.1005K. doi:10.1126/science.1180962. PMC 2789838. PMID 19779148. Lay summary â News-Medical.Net.
- RamÃrez BG, BlÃ¡zquez C, GÃ³mez del Pulgar T, GuzmÃ¡n M, de Ceballos ML (February 2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". J. Neurosci. 25 (8): 1904â13. doi:10.1523/JNEUROSCI.4540-04.2005. PMID 15728830.
- Milton NG (October 2002). "Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide". Neurosci. Lett. 332 (2): 127â30. doi:10.1016/S0304-3940(02)00936-9. PMID 12384227.
- Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (May 2002). "Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice". Proc. Natl. Acad. Sci. U.S.A. 99 (11): 7705â10. Bibcode:2002PNAS...99.7705L. doi:10.1073/pnas.092034699. PMC 124328. PMID 12032347.
- Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E (April 2013). "Effects of memantine and galantamine on cognitive performance in aged rhesus macaques". Neurobiol. Aging 34 (4): 1126â32. doi:10.1016/j.neurobiolaging.2012.10.020. PMID 23158762.
- McClean, P., Parthsarathy, V., Faivre, E., and HÃ¶lscher, C (November 2011). "The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease". The Journal of Neuroscience 31 (17): 6587â6594. doi:10.1016/S0968-0896(02)00251-1. PMID 12213471.
- Volicer L, Harper D, Manning B, Goldstein R, Satlin A (2001). "Sundowning and circadian rhythms in Alzheimer's disease". Am J Psychiatry 158 (5): 704â11. doi:10.1176/appi.ajp.158.5.704. PMID 11329390.
- Schmidt SD, Nixon RA, Mathews PM (2012). "Tissue processing prior to analysis of Alzheimer's disease associated proteins and metabolites, including AÎ²". Methods Mol. Biol. Methods in Molecular Biology 849: 493â506. doi:10.1007/978-1-61779-551-0_33. ISBN 978-1-61779-550-3. PMID 22528111.
- Schmidt SD, Mazzella MJ, Nixon RA, Mathews PM (2012). "AÎ² measurement by enzyme-linked immunosorbent assay". Methods Mol. Biol. Methods in Molecular Biology 849: 507â527. doi:10.1007/978-1-61779-551-0_34. ISBN 978-1-61779-550-3. PMID 22528112.
- Stine WB, Dahlgren KN, Krafft GA, LaDu MJ (March 2003). "In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis". J. Biol. Chem. 278 (13): 11612â22. doi:10.1074/jbc.M210207200. PMID 12499373.
- Gengler S, Gault VA, Harriott P, HÃ¶lscher C (June 2007). "Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background". Exp Brain Res 179 (4): 621â30. doi:10.1007/s00221-006-0819-6. PMID 17171334.
- Rekas A, Jankova L, Thorn DC, Cappai R, Carver JA (December 2007). "Monitoring the prevention of amyloid fibril formation by alpha-crystallin. Temperature dependence and the nature of the aggregating species". FEBS J. 274 (24): 6290â304. doi:10.1111/j.1742-4658.2007.06144.x. PMID 18005258.
- Sanghera N, Swann MJ, Ronan G, Pinheiro TJ (October 2009). "Insight into early events in the aggregation of the prion protein on lipid membranes". Biochim. Biophys. Acta 1788 (10): 2245â51. doi:10.1016/j.bbamem.2009.08.005. PMID 19703409.
- Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F (January 2008). "Lipids revert inert AÎ² amyloid fibrils to neurotoxic protofibrils that affect learning in mice". EMBO J. 27 (1): 224â33. doi:10.1038/sj.emboj.7601953. PMC 2206134. PMID 18059472.
- Istrate AN, Tsvetkov PO, Mantsyzov AB, Kulikova AA, Kozin SA, Makarov AA, Polshakov VI (January 2012). "NMR solution structure of rat AÎ²(1-16): toward understanding the mechanism of rats' resistance to Alzheimer's disease". Biophys J. 102 (1): 136â43. Bibcode:2012BpJ...102..136I. doi:10.1016/j.bpj.2011.11.4006. PMC 3250693. PMID 22225807.
This tab holds the annotation information that is stored in the Pfam database. As we move to using Wikipedia as our main source of annotation, the contents of this tab will be gradually replaced by the Wikipedia tab.
Beta-amyloid peptide (beta-APP) Provide feedback
No Pfam abstract.
External database links
This tab holds annotation information from the InterPro database.
InterPro entry IPR013803
Amyloid-beta precursor protein (APP, or A4) is associated with Alzheimer's disease (AD), because one of its breakdown products, amyloid-beta (A-beta), aggregates to form amyloid or senile plaques [PUBMED:16301322, PUBMED:16364896]. Mutations in APP or in proteins that process APP have been linked with early-onset, familial AD. Individuals with Down's syndrome carry an extra copy of chromosome 21, which contains the APP gene, and almost invariably develop amyloid plaques and Alzheimer's symptoms.
APP is important for the neurogenesis and neuronal regeneration, either through the intact protein, or through its many breakdown products [PUBMED:16406235]. APP consists of a large N-terminal extracellular region containing heparin-binding and copper-binding sites, a short hydrophobic transmembrane domain, and a short C-terminal intracellular domain. The N-terminal region is similar in structure to cysteine-rich growth factors and appears to function as a cell surface receptor, contributing to neurite growth, neuronal adhesion, axonogenesis and cell mobility [PUBMED:16406235]. APP acts as a kinesin I membrane receptor to mediate the axonal transport of beta-secretase and presenilin 1. The N-terminal domain can regulate neurite outgrowth through its binding to heparin and collagen I and IV, which are components of the extracellular matrix. APP is also coupled to apoptosis-inducing pathways, and is involved in copper homeostasis/oxidative stress through copper ion reduction, where copper-metallated APP induces neuronal death [PUBMED:12611883]. The C-terminal intracellular domain appears to be involved in transcription regulation through protein-protein interactions. APP can promote transcription activation through binding to APBB1/Tip60, and may bind to the adaptor protein FE65 to transactivate a wide variety of different promoters.
APP can be processed by different sets of enzymes:
- In the non-amyloidogenic (non-plaque-forming) pathway, APP is cleaved by alpha-secretase to yield a soluble N-terminal sAPP-alpha (neuroprotective) and a membrane-bound CTF-alpha. CTF-alpha is broken-down by presenilin-containing gamma-secretase to yield soluble p3 and membrane-bound AICD (nuclear signalling).
- In the amyloidogenic pathway (plaque-forming), APP is broken down by beta-secretase to yield soluble sAPP-beta and membrane-bound CTF-beta. CTF-beta is broken down by gamma-secretase to yield soluble amyloid-beta and membrane-bound AICD. Amyloid-beta is required for neuronal function, but can aggregate to form amyloid plaques that seem to disrupt brain cells by clogging points of cell-cell contact.
This entry represents the amyloid-beta peptide (A-beta), which originates as a breakdown product from the cleavage of amyloid-beta precursor protein (APP, or A4), an integral, glycosylated membrane brain protein.
More information about these protein can be found at Protein of the Month: Amyloid-beta Precursor Protein [PUBMED:].
The mapping between Pfam and Gene Ontology is provided by InterPro. If you use this data please cite InterPro.
|Cellular component||integral to membrane (GO:0016021)|
Below is a listing of the unique domain organisations or architectures in which this domain is found. More...
The graphic that is shown by default represents the longest sequence with a given architecture. Each row contains the following information:
- the number of sequences which exhibit this architecture
a textual description of the architecture, e.g. Gla, EGF x 2, Trypsin.
This example describes an architecture with one
Gladomain, followed by two consecutive
EGFdomains, and finally a single
- a link to the page in the Pfam site showing information about the sequence that the graphic describes
- the UniProt description of the protein sequence
- the number of residues in the sequence
- the Pfam graphic itself.
Note that you can see the family page for a particular domain by clicking on the graphic. You can also choose to see all sequences which have a given architecture by clicking on the Show link in each row.
Finally, because some families can be found in a very large number of architectures, we load only the first fifty architectures by default. If you want to see more architectures, click the button at the bottom of the page to load the next set.
Loading domain graphics...
We store a range of different sequence alignments for families. As well as the seed alignment from which the family is built, we provide the full alignment, generated by searching the sequence database using the family HMM. We also generate alignments using four representative proteomes (RP) sets, the NCBI sequence database, and our metagenomics sequence database. More...
There are various ways to view or download the sequence alignments that we store. We provide several sequence viewers and a plain-text Stockholm-format file for download.
We make a range of alignments for each Pfam-A family:
- the curated alignment from which the HMM for the family is built
- the alignment generated by searching the sequence database using the HMM
- Representative Proteomes (RPs) at 15%, 35%, 55% and 75% co-membership thresholds
- alignment generated by searching the NCBI sequence database using the family HMM
- alignment generated by searching the metagenomics sequence database using the family HMM
You can see the alignments as HTML or in three different sequence viewers:
- a Java applet developed at the University of Dundee. You will need Java installed before running jalview
- an HTML page showing the whole alignment.Please note: full Pfam alignments can be very large. These HTML views are extremely large and often cause problems for browsers. Please use either jalview or the Pfam viewer if you have trouble viewing the HTML version
- an HTML-based representation of the alignment, coloured according to the posterior-probability (PP) values from the HMM. As for the standard HTML view, heatmap alignments can also be very large and slow to render.
- Pfam viewer
- an HTML-based viewer that uses DAS to retrieve alignment fragments on request
You can download (or view in your browser) a text representation of a Pfam alignment in various formats:
You can also change the order in which sequences are listed in the alignment, change how insertions are represented, alter the characters that are used to represent gaps in sequences and, finally, choose whether to download the alignment or to view it in your browser directly.
You may find that large alignments cause problems for the viewers and the reformatting tool, so we also provide all alignments in Stockholm format. You can download either the plain text alignment, or a gzipped version of it.
We make a range of alignments for each Pfam-A family. You can see a description of each above. You can view these alignments in various ways but please note that some types of alignment are never generated while others may not be available for all families, most commonly because the alignments are too large to handle.
1Cannot generate PP/Heatmap alignments for seeds; no PP data available
Key: available, not generated, — not available.
Format an alignment
We make all of our alignments available in Stockholm format. You can download them here as raw, plain text files or as gzip-compressed files.
You can also download a FASTA format file containing the full-length sequences for all sequences in the full alignment.
MyHits provides a collection of tools to handle multiple sequence alignments. For example, one can refine a seed alignment (sequence addition or removal, re-alignment or manual edition) and then search databases for remote homologs using HMMER3.
HMM logos is one way of visualising profile HMMs. Logos provide a quick overview of the properties of an HMM in a graphical form. You can see a more detailed description of HMM logos and find out how you can interpret them here. More...
If you find these logos useful in your own work, please consider citing the following article:
This page displays the phylogenetic tree for this family's seed alignment. We use FastTree to calculate neighbour join trees with a local bootstrap based on 100 resamples (shown next to the tree nodes). FastTree calculates approximately-maximum-likelihood phylogenetic trees from our seed alignment.
Note: You can also download the data file for the tree.
Curation and family details
This section shows the detailed information about the Pfam family. You can see the definitions of many of the terms in this section in the glossary and a fuller explanation of the scoring system that we use in the scores section of the help pages.
|Number in seed:||2|
|Number in full:||171|
|Average length of the domain:||38.90 aa|
|Average identity of full alignment:||89 %|
|Average coverage of the sequence by the domain:||6.25 %|
|HMM build commands:||
build method: hmmbuild -o /dev/null HMM SEED
search method: hmmsearch -Z 23193494 -E 1000 --cpu 4 HMM pfamseq
|Family (HMM) version:||8|
|Download:||download the raw HMM for this family|
Weight segments by...
Change the size of the sunburst
selected sequences to HMM
a FASTA-format file
- 0 sequences
- 0 species
This visualisation provides a simple graphical representation of the distribution of this family across species. You can find the original interactive tree in the More....
This chart is a modified "sunburst" visualisation of the species tree for this family. It shows each node in the tree as a separate arc, arranged radially with the superkingdoms at the centre and the species arrayed around the outermost ring.
How the sunburst is generated
The tree is built by considering the taxonomic lineage of each sequence that has a match to this family. For each node in the resulting tree, we draw an arc in the sunburst. The radius of the arc, its distance from the root node at the centre of the sunburst, shows the taxonomic level ("superkingdom", "kingdom", etc). The length of the arc represents either the number of sequences represented at a given level, or the number of species that are found beneath the node in the tree. The weighting scheme can be changed using the sunburst controls.
In order to reduce the complexity of the representation, we reduce the number of taxonomic levels that we show. We consider only the following eight major taxonomic levels:
Colouring and labels
Segments of the tree are coloured approximately according to their superkingdom. For example, archeal branches are coloured with shades of orange, eukaryotes in shades of purple, etc. The colour assignments are shown under the sunburst controls. Where space allows, the name of the taxonomic level will be written on the arc itself.
As you move your mouse across the sunburst, the current node will be highlighted. In the top section of the controls panel we show a summary of the lineage of the currently highlighed node. If you pause over an arc, a tooltip will be shown, giving the name of the taxonomic level in the title and a summary of the number of sequences and species below that node in the tree.
Anomalies in the taxonomy tree
There are some situations that the sunburst tree cannot easily handle and for which we have work-arounds in place.
Missing taxonomic levels
Some species in the taxonomic tree may not have one or more of the main eight levels that we display. For example, Bos taurus is not assigned an order in the NCBI taxonomic tree. In such cases we mark the omitted level with, for example, "No order", in both the tooltip and the lineage summary.
Unmapped species names
The tree is built by looking at each sequence in the full alignment for the family. We take the name of the species given by UniProt and try to map that to the full taxonomic tree from NCBI. In some cases, the name chosen by UniProt does not map to any node in the NCBI tree, perhaps because the chosen name is listed as a synonym or a misspelling in the NCBI taxonomy.
So that these nodes are not simply omitted from the sunburst tree, we group them together in a separate branch (or segment of the sunburst tree). Since we cannot determine the lineage for these unmapped species, we show all levels between the superkingdom and the species as "uncategorised".
Since we reduce the species tree to only the eight main taxonomic levels, sequences that are mapped to the sub-species level in the tree would not normally be shown. Rather than leave out these species, we map them instead to their parent species. So, for example, for sequences belonging to one of the Vibrio cholerae sub-species in the NCBI taxonomy, we show them instead as belonging to the species Vibrio cholerae.
Too many species/sequences
For large species trees, you may see blank regions in the outer layers of the sunburst. These occur when there are large numbers of arcs to be drawn in a small space. If an arc is less than approximately one pixel wide, it will not be drawn and the space will be left blank. You may still be able to get some information about the species in that region by moving your mouse across the area, but since each arc will be very small, it will be difficult to accurately locate a particular species.
The tree shows the occurrence of this domain across different species. More...
We show the species tree in one of two ways. For smaller trees we try to show an interactive representation, which allows you to select specific nodes in the tree and view them as an alignment or as a set of Pfam domain graphics.
Unfortunately we have found that there are problems viewing the interactive tree when the it becomes larger than a certain limit. Furthermore, we have found that Internet Explorer can become unresponsive when viewing some trees, regardless of their size. We therefore show a text representation of the species tree when the size is above a certain limit or if you are using Internet Explorer to view the site.
If you are using IE you can still load the interactive tree by clicking the "Generate interactive tree" button, but please be aware of the potential problems that the interactive species tree can cause.
For all of the domain matches in a full alignment, we count the number that are found on all sequences in the alignment. This total is shown in the purple box.
We also count the number of unique sequences on which each domain is found, which is shown in green. Note that a domain may appear multiple times on the same sequence, leading to the difference between these two numbers.
Finally, we group sequences from the same organism according to the NCBI code that is assigned by UniProt, allowing us to count the number of distinct sequences on which the domain is found. This value is shown in the pink boxes.
We use the NCBI species tree to group organisms according to their taxonomy and this forms the structure of the displayed tree. Note that in some cases the trees are too large (have too many nodes) to allow us to build an interactive tree, but in most cases you can still view the tree in a plain text, non-interactive representation. Those species which are represented in the seed alignment for this domain are highlighted.
You can use the tree controls to manipulate how the interactive tree is displayed:
- show/hide the summary boxes
- highlight species that are represented in the seed alignment
- expand/collapse the tree or expand it to a given depth
- select a sub-tree or a set of species within the tree and view them graphically or as an alignment
- save a plain text representation of the tree
Please note: for large trees this can take some time. While the tree is loading, you can safely switch away from this tab but if you browse away from the family page entirely, the tree will not be loaded.
There is 1 interaction for this family. More...
We determine these interactions using iPfam, which considers the interactions between residues in three-dimensional protein structures and maps those interactions back to Pfam families. You can find more information about the iPfam algorithm in the journal article that accompanies the website.
For those sequences which have a structure in the Protein DataBank, we use the mapping between UniProt, PDB and Pfam coordinate systems from the PDBe group, to allow us to map Pfam domains onto UniProt sequences and three-dimensional protein structures. The table below shows the structures on which the Beta-APP domain has been found. There are 133 instances of this domain found in the PDB. Note that there may be multiple copies of the domain in a single PDB structure, since many structures contain multiple copies of the same protein seqence.
Loading structure mapping...